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Abstract
Objective
The impetus for this consensus discussion was to recommend clinical trial designs that can
deliver high-quality data for eﬀective therapies for pediatric patients, in a reasonable timeframe,
with a key focus on short- and long-term safety.
Methods
The International Pediatric Multiple Sclerosis Study Group convened a meeting of experts to
review the advances in the understanding of pediatric-onset multiple sclerosis (MS) and the
advent of clinical trials for this population.
Results
In the last few years, convincing evidence has emerged that the biological processes involved in
MS are largely shared across the age span. As such, treatments proven eﬃcacious for the care of
adults with MS have a biological rationale for use in pediatric MS given the relapsing-remitting
course at onset and high relapse frequency. There are also ethical considerations on conducting
clinical trials in this age group including the use of placebo owing to highly active disease. It is
imperative to reconsider study design and implementation based on what information is
needed. Are studies needed for eﬃcacy or should safety be the primary goal? Further, there have
been major recruitment challenges in recently completed and ongoing pediatric MS trials.
Phase 3 trials for every newly approved therapy for adult MS in the pediatric MS population are
simply not feasible.
Conclusions
A primary goal is to ensure high-quality evidence-based treatment for children and adolescents
with MS, which will improve our understanding of the safety of these agents and remove
regulatory or insurance-based limitations in access to treatment.
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The diagnosis of multiple sclerosis (MS) in children is en-
abled by diagnostic criteria.1,2 Genetic and environmental risk
factors contributing to MS susceptibility are shared between
pediatric- and adult-onset disease.3–6 Pathologic analyses sup-
port the same pathologic features of perivenular inﬂammation,
focal demyelinating plaques, and axonal injury.7
Pediatric MS follows a relapsing-remitting (RR) course, with
a high relapse frequency.8,9 MRI features are similar in lesion
distribution as adult-onset MS, with the rate of lesion accrual
being potentially higher in pediatric patients.10–12 Despite
frequent relapses and MRI evidence of active disease, pediatric
patients with MS rarely accrue signiﬁcant physical disability in
the ﬁrst decade after disease onset.13 In contrast, clear cognitive
changes occur even within the ﬁrst year after disease onset,
raising the issue of early treatment intervention.14,15
The literature regarding treatment of pediatric MS is largely
restricted to retrospective studies of ﬁrst-line injectable thera-
pies, a few of the oral agents, and natalizumab. While such
analyses cannot formally address treatment eﬃcacy, the avail-
able data support eﬀectiveness as compared to pretreatment, as
well as a similar tolerability and short-term safety proﬁle as has
been documented for these agents in adult RRMS trials.16–26
Several studies, including a high-proﬁle meta-analysis, support
MRI lesions as a valid surrogate endpoint for clinical relapses
in RRMS,27 opening new possibilities for pediatric trials.
Our goals are to review the current state of pediatric MS
clinical trials and lessons learned over the last 6 years and
provide consensus recommendations for future trials.
Current status of clinical trials in
pediatric MS
To date, clinical trials of promising MS agents are typically
performed in patients 18 years and above. The Food and Drug
Administration (FDA), as a consequence of the Pediatric Re-
search Equity Act (congress.gov/108/plaws/publ155/PLAW-
108publ155.pdf), and the EuropeanMedicines Agency (EMA),
as a consequence of the Paediatric Regulation (ema.europa.
eu/ema/index.jsp?curl=pages/regulation/document_listing/
document_listing_000068.jsp&mid=WC0b01ac0580925c45),
mandate pediatric investigation plans to test safety and ef-
ﬁcacy of new agents for patients under the age of 18 for drugs
approved in adults. As a result, over the last 6 years, 5 clinical
trials testing 4 agents have been launched in pediatric MS
(table 1).
Strong correlations between treatment eﬀect on relapse rate and
MRI lesion accrual have been reported both in adult and pe-
diatric MS.27–29 These correlations emphasize the crucial role
of MRI in clinical trials of MS agents with anti-inﬂammatory
properties. In particular, a large meta-analysis published in
201327 validated the role of MRI lesions as a surrogate
endpoint for clinical relapses in RRMS, conﬁrming previous
results28 and validating the quantitative relationship that
allows estimation of the treatment eﬀect on relapses from an
observed eﬀect onMRI lesions.27 These ﬁndings have strong
implications for the design of pediatric trials testing drugs
already studied in the adult RRMS population.
Methods for the updated consensus
The International Pediatric Multiple Sclerosis Study Group
(IPMSSG) is a group of international pediatric MS care pro-
viders that was established in 2005. The IPMSSG (ipmssg.org/)
goals regarding the advancement of clinical care in pediatric MS
are listed in table 2. There are currently 165members registered
with the IPMSSG representing 44 countries. The IPMSSG
has a Steering Committee (SC) made of 9 members elected by
the membership for a 3-year term, renewable once. In 2012, the
IPMSSG held their ﬁrst international meeting dedicated to
clinical trials in pediatricMS and appointed a Clinical Trial Task
Force (CTTF) to speciﬁcally address issues related to clinical
trials in this age group.30 TheCTTF is composed of 4members,
elected every 3 years by the IPMSSG SC. TheCTTF has several
core responsibilities, key among them the careful vetting of
Pediatric Investigation Plans, which are now mandated by the
FDA and the EMA for new agents developed in adults.
The IPMSSG SC and several national MS Societies recog-
nized the need to convene a meeting to update the consensus
for clinical trials in pediatric MS.30 This meeting was hosted
by the Canadian and US MS societies, and included key
stakeholders representing MS societies and patients’ per-
spectives. In addition to the IPMSSG SC, an MS clinical trial
statistician (M.-P.S.) and an ethicist (Dr. Alison Bateman-
House) specialized in clinical trials were invited to join the
meeting to share their expertise with the group. This group of
14 individuals met in New York City on January 18 and 19,
2018. A consensus was established that is outlined below,
which was then vetted by IPMSSG members to ensure broad
representation. Of the 162 members who were contacted, 70
Glossary
CTTF =Clinical Trial Task Force;DMT = disease-modifying therapies; EMA = EuropeanMedicines Agency; FDA = Food and
Drug Administration; IPMSSG = International Pediatric Multiple Sclerosis Study Group; MS = multiple sclerosis; PD =
pharmacodynamic; PK = pharmacokinetic; RCT = randomized controlled trial; RR = relapsing-remitting; SC = Steering
Committee; SDMT = Symbol Digit Modalities Test.
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from 23 countries provided feedback with only one dis-
agreeing with some of the recommendation wording.
During the meeting, the group reviewed progress since the
2012 consensus paper,30 and identiﬁed areas of agreement
to implement in future trials of newMS agents and areas that
needed additional discussions. The literature concerning pe-
diatric MS and use of MS therapeutic agents in pediatric MS
was reviewed as well as new unpublished data pertaining to use
of disease-modifying therapies (DMT) in various countries,
and clinical trial design options with respective power. Feed-
back from physicians providing care for pediatric MS, most of
whom had participated in clinical trials, was obtained in 2017
by the CTTF, and the perspectives from patients and their
families regarding pediatric MS clinical trials were obtained
through surveys performed in England and France in 2017.31,32
Table 3 provides the key recommendations of the IPMSSG
SC, for which 100% agreement was reached.
Status of clinical trials in pediatric MS
Three clinical trials of agents approved for the treatment of
adult relapsing-remitting MS were completed in the pediatric
population in 2014 and 2017 (table 1). The natalizumab
pharmacokinetic/pharmacodynamic (PK/PD) study was
a 16-week open-label study (NCT01884935) completed in
2014. FOCUS was a 6-month open-label study of dimethyl
fumaric acid 240 mg twice a day in children 30 kg or more
completed in 2016.24 This study is followed by a 2-year open-
label extension. PARADIGMS was a phase 3 randomized
controlled trial (RCT), with double dummy design compar-
ing ﬁngolimod vs weekly IM interferon-β-1a for up to 2
years.25 This study is followed by a 5-year open-label exten-
sion. Three trials are ongoing with teriﬂunomide, dimethyl
fumaric acid, and alemtuzumab (table 1).
Status of therapeutic access
Despite the paucity of clinical trial evidence, several MS ther-
apies are available (sometimes approved) to treat pediatric MSTa
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Table 2 International Pediatric Multiple Sclerosis Study
Group vision to advance care in pediatric
multiple sclerosis (MS)
To evaluate the safety and efficacy of appropriate therapies for childrenwith
MS with the following goals:
Providing useful, actionable data for neurologists caring for patients
Providing parents and patients with clear data regarding treatments
Facilitating regulatory approval of appropriate therapies
Facilitating access and affordability of appropriate therapies
Increasing the breadth of appropriate and informed treatment options
for pediatric MS
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depending on the country, occasionally with variability within
countries based on provincial rules. Examples include in-
terferon-β and glatiramer acetate in Italy, England, France
(with special precaution under 12), theNetherlands, Argentina,
Canada, and the United States. While natalizumab is available
in France (>12 years of age), the Netherlands, England, Italy,
Argentina, and Canada for patients with breakthrough disease
on interferon or glatiramer acetate, it is available in the United
States for most pediatric patients depending on health in-
surance restrictions and availability of infusion centers certiﬁed
for drug administration. Teriﬂunomide is available in England,
Canada, and the United States for pediatric MS. Fingolimod is
now approved for children between 10 and 18 years in the
United States, Europe, Argentina, and Canada. Over the last
6 years, the availability of some DMT for children and
teenagers with MS and the recognition of an early clinical
impact of the disease, especially on cognition, have prompted
recommendations to initiate treatment shortly after diagnosis.33
These considerations, in addition to the regulatory approval of
ﬁngolimod in several countries as ﬁrst-line therapy, aﬀect the
feasibility and ethics of future placebo or active comparator
clinical trials in pediatric MS, including the choice of an active
control.
Challenges of pediatric MS
clinical trials
Several challenges have been identiﬁed in the last 5 years
through the conduct of clinical trials in the pediatric age group.
Time to complete study enrollment
The ﬁrst randomized active comparator phase 3 trial in pe-
diatric MS (PARADIGMS) took 3 years (July 2013–August
2016) to enroll 215 participants at 80 centers in 25 countries
to achieve enrolment. TERIKIDS is a phase 3 randomized
placebo-controlled study that took 3.5 years (June 2015–
January 2018) to enroll 166 patients among 77 sites in 22
countries. Enrollment times were substantially protracted
relative to adult trials of the same agents. The reasons un-
derpinning the slow enrollment in pediatric MS trials include
(1) the limited pool of possible candidates, which necessitated
addition of numerous study sites, leading to a prolonged
launch period; (2) the limited prior clinical trial experience by
participating sites hindered timely site preparedness; and (3)
a low rate of consent from eligible participants and their
families, who cited issues with the study design, time to travel
to sites, and the burden of frequent study visits.31
Risk of incomplete enrollment
The protracted timeline for clinical trials in pediatric MS may
lead to incomplete enrollment.32 Incomplete trials (a.k.a.
“ghost trials”) are inadequately powered to meet study end-
points, leaving enrolled participants and the entire pediatric
MS community without the requisite data regarding safety
and eﬃcacy of the agent under study.34
Limited pool of possible clinical
trial candidates
In the United States, the prevalence of pediatric MS is esti-
mated at less than 5,000 patients.35,36 This is in contrast with
up to 800,000 American adults living with MS.37 While
worldwide prevalence data are lacking, a conservative estimate
suggests that there are fewer than 10,000 pediatric MS
patients currently younger than age 18 years. As median age at
Table 3 Consensus International Pediatric Multiple
Sclerosis StudyGroup recommendations for future
clinical trials in pediatric multiple sclerosis (MS)
Regulatory recommendations
(1) Regulatory agencies from different world regions should harmonize
clinical trial design requirements for pediatric MS therapeutic trials of
immunomodulating agents.
(2) No more than one phase 3 clinical trial should be performed for the
same pharmacologic agent.
(3) In vitro and animal studies related to the use of a drug in the pediatric
population should be performed early on to avoid postponing the
appropriate testing in this age group in humans.
(4) Pediatric PK/PD studies should be completed for all new agents
amenable to PK/PD testing to allow identification of the appropriate
dose in children.
Trial design recommendations
(5) Placebo-controlled trials of immunomodulatory agents proven
effective in adult MS are inappropriate in pediatric MS.
(6) Future registration trials (phase 3) in adults should consider enrollment
of teenagers in some situations.
(7) For drugs that have been well-studied in adults, and have
demonstrated, through pharmacodynamic and statistical modeling,
extrapolated predictions for the pediatric age range that would
support efficacy, then open-label study (including PK/PD and safety
endpoints) should be considered as sufficient for registration in
pediatric MS.
(8) In the case that an open-label study (including PK/PD and safety
endpoints) is deemed insufficient for registration in pediatric MS,
a short controlled trial with anMRI primary endpoint is recommended
rather than a clinical endpoint, provided that the pivotal study of the
same agent in adult-onset MS demonstrated a robust relationship
between clinical efficacy and MRI endpoints.
(9) For randomized controlled trials of immunomodulating agents, the
control drug could be fingolimod or other drugs commonly used in
pediatric MS.
(10) For agents for which a phase 3 trial with a clinical primary endpoint is
mandated by regulatory agencies, time to event (relapse) analyses
(rather than annualized relapse rate) should be favored as this design
allows a prompter switch to more effective therapies.
(11) For add-on trials, the new agent (such as a therapy with potential
remyelinating or neuroprotective properties, nutraceuticals, or
others) could be compared to placebo, provided that
immunomodulatory therapies are maintained.
Safety monitoring recommendations
(12) Open-label extension studies should bemandated for all clinical trials
in pediatric MS populations.
(13) Open-label studies or registries should be designed tomonitor safety
in patients 12 and under.
Abbreviations: PD = pharmacodynamic; PK = pharmacokinetic.
Neurology.org/N Neurology | Volume 92, Number 22 | May 28, 2019 e2541
pediatric MS onset is 15 years, patients remain in the pediatric
age group for a limited time after diagnosis.38
Site-specific challenges in pediatric MS trials
Many investigators who participated in the ﬁrst pediatric MS
trials had never participated in trials before. Finding appro-
priate research coordinator support for a study that would
enroll very few patients at a given site, navigating regulatory
issues, and planning for an appropriate budget were some of
the challenges encountered.31 Furthermore, as exempliﬁed by
the PARADIGMS study, a pediatrician had to be identiﬁed for
several visits to conﬁrm Tanner stage and normal de-
velopment, in addition to the treating and Expanded Dis-
ability Status Scale neurologists, and the physician overseeing
the ﬁrst-dose administration. As such, multiple providers were
required for a very small number of enrolled participants.
Financial risk
Most sites participating in the ﬁrst pediatric MS trials enrolled
between 0 and 2 patients. This means sites invested a con-
siderable amount of time and energy upfront to complete
regulatory work despite low expected enrollment, which was
often not remunerated given low per-patient reimbursement.
Coordinator support was particularly ﬁnancially diﬃcult as
the number of planned participants was insuﬃcient to justify
full-time support yet many smaller sites do not have a pool of
coordinators capable of providing part-time hours. Finally,
low per-site enrollment also increases per-site costs for
companies sponsoring the trials given their time investment in
site launch and costs for monitors who visited sites for only
a few participants.
Patients and family endorsement
Prior to 2013, there had never been any clinical trials of agents
for pediatric MS. As such, parents and patients had no prior
exposure to clinical trial options and to the implications of
participation. A survey conducted in England and France, and
focus groups conducted in the United States with pediatric
patients with MS and their parents, emphasized that it was
challenging for families to take time oﬀ fromwork and school to
participate in a trial.32 Childrenwere often altruistic and eager to
contribute to science. Parents expressed concerns about the
safety of new drugs and the possibility to be randomized to
placebo or a potentially less eﬃcacious drug. Further com-
pounding parental and patient decision-making is the oﬀ-label
access to the medication under study in some countries. Finally,
a double-dummy design did not resonate with some families,
who disliked the idea of placebo injections. However, most
families expressed interest in participating in future clinical trials.
Consequences of the ﬁrst completed
phase 3 RCT in pediatric MS
PARADIGMSwas the ﬁrst RCT completed in pediatricMS.25
The study showed superiority of ﬁngolimod to weekly IM
interferon-β-1a treatment for the primary (annualized relapse
rate) and secondary endpoints. Several consequences are
expected from the trial results. First, the feasibility of con-
ducting and completing MS trials in this age group was
demonstrated, despite prolonged enrollment period. Second,
demonstration of eﬃcacy was achieved with a modest sample
size (approximately 100 participants per study arm). Third,
the trial results have led to the approval of ﬁngolimod for
patients with pediatric MS (age 10 years and older) in several
countries. Of note, approval for use of ﬁngolimod in pediatric
MS occurred 8 years following the initial approval in adultMS.
While PARADIGMS provides the ﬁrst level 1A evidence of
eﬀectiveness of a therapeutic agent in pediatric MS, other
therapies, notably typical ﬁrst-line treatments such as in-
terferon-β and glatiramer acetate, remain appropriate for
some patients and have over 15 years of safety data in that age
group. Deﬁning which pediatric patients with MS would be
better served by ﬁngolimod requires careful clinical and family
dialogue. Finally, the higher eﬃcacy of ﬁngolimod compared
to weekly interferon in the pediatric trial raises the question of
what agent should be used as active comparators in future
trials, which in turn will aﬀect power considerations.
Consensus on trial designs for
pediatric MS
The SC reviewed information from other pediatric disorders
for which agents are typically tested ﬁrst in adults with the
disease. The situation for antiepileptic agents was particularly
informative.39,40 In the context of speciﬁc pediatric epilepsies,
the FDA has accepted the extrapolation of eﬃcacy to pediatrics
based on adult trial data down to age 2 years, with a re-
quirement for only PK and PD study.39,40 The decision tomake
this extrapolation rested on evidence that mechanisms and
pathobiology was shared across the age span. The IPMSSG SC
reviewed and endorsed the considerable evidence supporting
the contention that MS is also an age span disease.3–7
The SC agreed that further studies of MS treatments are
needed in pediatric MS to provide information, including
dosing, on alternate drugs, especially for newer agents with
diﬀerent mechanisms of action and safety proﬁles. The SC
agreed that trial design should be chosen according to the class
of medication (i.e., anti-inﬂammatory vs neuroprotection vs
restorative/remyelination).
Consensus recommendation for regulatory agencies: Pediat-
ric PK/PD studies should be completed for all new agents
amenable to PK/PD testing to allow identiﬁcation of the
appropriate dose in children.
Ethical considerations
The principle of nonmaleﬁcence in medical ethics requires
that a procedure does not harm the patient involved or others.
All members of the group emphasized ethical concerns about
studies that included the use of placebo.41,42
e2542 Neurology | Volume 92, Number 22 | May 28, 2019 Neurology.org/N
Based on the evidence that RRMS in children and adolescents
is associated with a higher relapse rate and more rapid accrual
of new lesions relative to adult-onset disease and that highly
active disease associates with a higher risk of future disability,
the group proposed the following:
Consensus recommendation for trial design: Placebo-controlled
trials of immunomodulatory agents proven eﬀective in adult MS
are inappropriate in pediatric MS.
Other approaches for studying medications that are already
registered for adults but need further evaluation in the pediatric
age group to address safety rather than focus on eﬃcacy include
(1) limiting investigation to PK/PD studies to inform dosing
for the pediatric age group or (2) clinical trial designs with
shorter duration (such as 6 months) that include MRI rather
than clinical endpoints. For drugs not yet approved in adults, it
was suggested to consider enrollment of those 12 years and
older in future registration phase 3 trials of adult MS (see next
section). In either scenario, it is critical to enroll pediatric
patients with MS into open-label registries that monitor long-
term safety of new agents including those under the age of 12.
Inclusion of children in adult studies
The SC debated on the ethics and feasibility of enrolling
teenagers in phase 3 trials performed in adults with MS to
promote early access of younger patients to new treatments at
the time of approval. The consensus was that this might be
considered only for agents with strong safety data in adult MS
phase 2 trials, strong safety data already established in phase 2
and 3 trials for conditions other than MS, for agents (such as
vitamin D) for which safety data exist in other pediatric pop-
ulations, and for agents with promising safety based on PK/PD
studies in pediatric MS. It was considered reasonable to avoid
exposure of young children such as those who are in the pre-
adolescent age range to new agents under development for
which safety was not yet demonstrated.
Consensus recommendation for clinical trial design: Future
registration trials (phase 3) in adults should consider enroll-
ment of teenagers in some situations.
Clinical trial designs
The group agreed that trial design should be chosen according
to the primary class of medication (i.e., anti-inﬂammatory vs
neuroprotection vs restorative/remyelination).
Anti-inflammatory agents
The SC discussed feasible trial designs to test anti-
inﬂammatory agents already approved after phase 3 trials in
adult MS. A fundamental consideration is to design trials that
can feasibly enroll in a timeframe that advances access to
eﬀective therapies. Study designs requiring very large cohorts
need to be avoided to prevent ghost trials.
Consensus recommendations for trial design:
c For drugs that have been well-studied in adults, and have
demonstrated, through pharmacodynamic and statistical
modeling, extrapolated predictions for the pediatric age
range that would support eﬃcacy, then open-label study
(including PK/PD and safety endpoints) should be
considered as suﬃcient for registration in pediatric MS.
Data extrapolated from young adult datasets and Bayesian
analysis may be used to augment eﬃcacy data.43
c In the case that an open-label study (including PK/PD and
safety endpoints) is deemed insuﬃcient for registration in
pediatric MS, a short controlled trial with an MRI primary
endpoint is recommended rather than a clinical endpoint,
provided that the pivotal study of the same agent in adult-
onset MS demonstrated a robust relationship between
clinical eﬃcacy and MRI endpoints. Two independent
meta-analyses conﬁrmed that treatment eﬀect on relapses
can be precisely estimated by the eﬀect observed on
MRI lesions in adults for all the approved drugs, giving
a solid base to this recommendation.27,28 The results of
the second meta-analysis,27 validating the results of the
previous one,28 give the rationale to regulatory agencies
to accept MRI markers formally as surrogate outcomes
in pediatric MS trials. Such trial designs will require fewer
participants, given the greater treatment eﬀect measured
byMRI relative to clinical outcomes (such as relapse rate),
and can be achieved using a shorter trial duration (typically
6 months), making these trials more feasible in children.
Given thatMRI as a primary outcomemay not be permitted
by regulatory agencies for all such trials, we recommend the
following:
Consensus recommendation for trial design: For agents for
which a phase 3 trial with a clinical primary endpoint is
mandated by regulatory agencies, time to event (relapse)
analyses (rather than annualized relapse rate) should be fa-
vored as this design allows a more rapid switch to therapies
with superior eﬃcacy.44
The SC discussed that ideally one study with multiple drug
arms could be appealing. However, such studies would be
challenging to implement as timelines to test agents may vary
due to pediatric investigation plan pressures, and sequence of
study visits and safety monitoring may vary depending on the
agent. The funding mechanism of a trial evaluating drugs
manufactured by diﬀerent companies seemed to be an addi-
tional challenge diﬃcult to address unless funding was chan-
neled through research foundations or public research entities.
Neuroprotection and remyelination
The potential for current therapies to enhance remyelination
and neuronal/axonal repair remains unclear. As trials emerge
exploring compounds with potential neuroprotective or
neuroreparative mechanisms, such drugs are likely to be
added to ongoing immunomodulatory treatments (at least in
RR disease, which is the only form of MS seen in the pediatric
Neurology.org/N Neurology | Volume 92, Number 22 | May 28, 2019 e2543
population).When such treatments are available for study, the
following recommendation was proposed:
Consensus recommendation for trial design: For add-on trials,
the new agent (such as a therapy with potential remyelinating
or neuroprotective properties, nutraceuticals, or others) could
be compared to placebo, provided that immunomodulatory
therapies are maintained.
Regulatory issues
Harmonization of regulatory guidelines
Over the last 6 years, the SC has been concerned with the
heterogeneity of FDA and EMA requirements for clinical trial
design for pediatric MS. Examples of study designs utilized in
pediatric MS include a double-dummy active control design
for PARADIGMS, a placebo-controlled design for TER-
IKIDS, an open-label randomized trial with active control for
CONNECT, and open-label observational study for LEM-
KIDS (table 1). This lack of harmonization has led to highly
diverse designs for the ongoing trials, inherently limiting
ability to compare clinical trials to one another. The imper-
ative to gain consistent clinical outcome data from therapeutic
trials leads to the following:
Consensus recommendation for regulatory agencies: Regu-
latory agencies from diﬀerent world regions should harmonize
clinical trial design requirements for pediatric MS therapeutic
trials of immunomodulating agents.
Furthermore, diﬀering opinions between regulatory agencies
has also led to diﬀerent clinical trial designs for the same drug
in diﬀerent world regions, as in the case of dimethyl fumarate,
where at least 3 studies have been launched. Given the limited
number of pediatric patients with MS, having competing tri-
als, particularly for single agent, has a negative eﬀect on the
ability to fully recruit and runs the risk of ghost trials. The SC
hopes to work with the EMA and FDA so harmonized rec-
ommendations can be used for the design of future clinical
trials in pediatric MS, and strongly endorses the following:
Consensus recommendation for regulatory agencies: No
more than one phase 3 clinical trial should be performed
for the same pharmacologic agent. Harmonizing regulatory
requirements from diﬀerent world regions is required to
ensure a single study per new agent if the study enrolls across
multiple countries.
Pediatric in vitro and in vivo models
The FDA and EMA should consider not only data from adult
MS studies, but also preclinical data informing on risks relative
to the pediatric populations. If such studies are requested only
after completion of the phase 3 studies in adults, then the
design and launch of pivotal trials in pediatric MS are delayed.
Consensus recommendation for regulatory agencies: In vitro
and animal studies related to the use of a drug in the pediatric
population should be performed early on to avoid postponing
the appropriate testing in this age group in humans.
Reporting of trial results
The SC also agreed that any results from trials performed in
pediatric MS participants should be presented and made
available to the public within 12 months of result analyses as
requested by the NIH (clinicaltrials.gov), so treatment deci-
sions could be implemented timely in young patients.
Strategies to enhance patient
participation in trials
Based on the experience of the SC and broader feedback
coming from a survey of the IPMSSG membership, it was
recommended that several approaches should be considered
to ease participation in pediatric MS trials considering the
substantial time commitment for children (i.e., school) and
parents (i.e., work).31 Trial designs should limit the number of
in-person visits and consider use of telephone or virtual tel-
ehealth visits when feasible for safety monitoring visits.
Scheduling of such visits could also occur during after school
hours or on weekends to reduce school absenteeism. Out-
come metrics that engage the pediatric population, such as
symptom tracking via applications downloaded onto mobile
devices, are future considerations. The use of a local labora-
tory for safety biological tests or a visiting nurse would be
additional steps towards decreasing the burden for families
participating in trials. Provision of parental compensation to
cover time lost at work when bringing their child for study
visits or costs associated with care of young siblings should be
considered in study budgets. Finally, study visits should be
shortened and eﬃciency of the visit maximized.
To that end, it is recommended that a short cognitive screening
approach with only one or just a few tests be included. This
diﬀers from the prior recommendation in 2013 since that
proposed battery was 45minutes ormore in length and diﬃcult
to implement. Brief cognitive screening approaches that have
been successfully studied in pediatric MS include a pediatric
version of the 3-test Brief International Cognition Assessment
in MS (BICAMS,45 the Symbol Digit Modality Test
[SDMT],46 a computer administered version of the SDMT,47
or other brief sensitive computer-administered measures).45
While the value of MRI as either a primary or secondary
outcome is endorsed, the frequency of imaging should be
carefully considered. For example, in 2-year trials, annual
brain MRI scans were believed appropriate as this frequency
would match clinical practice. The group also agreed that
administration of IV contrast products were only necessary
at baseline to better deﬁne disease activity, but was not
necessary for subsequent MRI scans as the number of new or
enlarging T2-bright foci was a more reliable endpoint than
contrast-enhancing lesions in studies with infrequent scans.
Limiting the use of contrast agents addressed both a parental
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concern regarding the possible long-term toxicity of re-
peated administration of these agents48 and also shorter
duration of study visits.
Long-term safety data are arguably one of the most important
facets required to advance the care of pediatric MS patients,
and to ensure that treatment during childhood and adoles-
cence does not expose patients to future risk. Given this, the
SC strongly endorses the following:
Consensus recommendations for safety monitoring: Open-
label extension studies should be mandated for all clinical trials
in pediatricMS populations. Given thatmonitoring participants
as they transitioned to college, sometimes moving far away
from home, the use of novel participant interaction methods,
such as mobile device patient-entered data, could help maxi-
mize retention in this critical phase of safety monitoring.
The SC recognized that most trials did not enroll pediatric
patients withMS under the age of 10, and that those enrolled in
the 10–12 years age category were very few, to some extent
limiting safety information for new drugs in the very young. It
was recognized that this age group is very small (i.e., represents
20% or so of all pediatric patients with MS), and that their
participation in trials is more challenging than teenagers, as,
for example, brain MRI scans may require sedation in the
very youngest children. Given that no clinical trial is likely to
be powered to measure eﬃcacy in this age group, the SC
proposes the following:
Consensus recommendations for safety monitoring: Open-
label studies or registries should be designed to monitor safety
in patients 12 and under.
Future directions
The SC was pleased to see the overall progress regarding care,
access to DMT, and testing of new agents for pediatric MS in
the last 6 years but acknowledged several critical areas that
should be addressed by future research in that age group.
Notably, priorities should include the validation of telehealth/
remote visits, the development of clinical trial designs based
on MRI variables as a surrogate endpoint, and the harmoni-
zation of regulatory requirements for testing of new treat-
ments in pediatric MS. Speciﬁc inclusion criteria should also
be reﬁned for enrollment in pediatric MS clinical trials in the
future such as serostatus for aquaporin-4 and myelin oligo-
dendrocyte glycoprotein immunoglobulin G. Future work
will determine the role of brain volume, optical coherence
tomography, and serum levels of neuroﬁlament as possible
outcome measures of interest for clinical trials.
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